ObvioHealth raises $3 million to facilitate mobile clinical trials
Date: 2018-03-25   Author: Paroma Bhattacharya  Category: #news

ObvioHealth, one of the notable “site-less” clinical trial companies of Singapore, recently announced raising $3 million in a Series A funding round. Reportedly, the financing will help the firm in supporting its operational team and present growth requirements. The funding round has been led by TSK I, a venture fund that chiefly focuses on life science and healthcare initiative financing.

As per reliable sources, ObvioHealth will be digitizing the entire process in order to comply with Food and Drug Administration (FDA) Good Clinical Practices. The company has also been focusing on facilitating cost efficient and faster clinical trials.

For the record, ObvioHealth’s proprietary software, ClaimIt, supports interventional and observational studies, allowing real-time interactions with subjects, as well as integration with smartphones and connected devices.

CEO of ObvioHealth, Bryan Silverman reportedly said that CliamIt has become a go-to platform for sponsors who value cost and time savings that online clinical trials through ClaimIt can offer. He went on to add that ClaimIt is generating significant traction through its digital platform in therapeutic areas as it facilitates expensive and complex studies within the traditional model.

The venture fund TKS I has been formed by the SPRIM Ventures, the VC arm of SPRIM and Tikehau Investment Management. SPRIM is a global innovation firm focused on healthcare while Tikehau Investment Management is an investment and asset management group which manages assets that surpass US$17 billion in value.

In a statement, Tikehau IM Chairman Bruno de Pampelonne reportedly said that technology is to be thanked for the disruption caused in clinical trial industry. He further added that the firm is excited to receive this opportunity to support the growth of ObvioHelath with the Series A financing round. He expressed belief that since ObvioHelath is led by a team of experienced professionals with a detailed vision, the firm would soon become one of the global leaders in mobile clinical trial.



About Author


Paroma Bhattacharya

Paroma Bhattacharya

Paroma currently works as a content developer for AlgosOnline. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched content in diverse fields. Apart from...

Read More

More from Paroma


Post Recommendents

Ford introduces new mid-size SUV in China to revive falling sales
Author: Pankaj Singh

Ford Motor Co. has recently launched a new mid-size SUV in China, as it looks to revive diminishing sales in the biggest car market of the world. The Ford Territory, developed along with the local partner Jiangling Mot...


Global Stand-Up Pouch Valves Market to exceed 25 billion units by 2024
Author: Rahul Varpe

Most participants in stand-up pouch valves market are looking forward to investing in advanced and efficient machine solutions. In fact, several packaging producers have already installed machine-based packaging facilities in order to fulfill the ...


Canopy Growth buys assets of hemp researcher Ebbu Inc for C$429m
Author: Saif Ali Bepari

Canopy Growth Corporation has reportedly announced that it has signed an agreement to acquire the assets of ebbu, Inc., a leading hemp research firm based in Colorado. As per trusted sources, the transaction is said to...